Back to results

Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER®)

Primary Purpose

Diabetes, Diabetes Mellitus, Type 2

Status

Completed

Phase

Phase 3

Locations

International

Study Type

Interventional

Intervention

liraglutide

placebo

About this trial

This is an interventional treatment trial for Diabetes

Eligibility Criteria

50 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: - Type 2 diabetes - Age min. 50 years at screening and concomitant cardiovascular, cerebrovascular or peripheral vascular disease or chronic renal failure or chronic heart failure OR age min. 60 years at screening and other specified risk factors of cardiovascular disease - HbA1c: 7.0% or above - Anti-diabetic drug naive or treated with one or more oral anti-diabetic drugs (OADs) or treated with human NPH insulin or long-acting insulin analogue or premixed insulin, alone or in combination with OAD(s) Exclusion Criteria: - Type 1 diabetes - Use of a glucagon-like peptide-1 (GLP-1) receptor agonist (exenatide, liraglutide or other) or pramlintide or any dipeptidyl peptidase 4 (DPP-4) inhibitor within the 3 months prior to screening (trial start) - Use of insulin other than human NPH insulin or long-acting insulin analogue or premixed insulin within 3 months prior to screening. Short-term use of other insulin during this period in connection with intercurrent illness is allowed, at Investigator's discretion

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Liraglutide

Placebo

Arm Description

Outcomes

Primary Outcome Measures

Time From Randomisation to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome)

Time from randomisation to first occurrence of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke (a composite cardiovascular outcome). The percentage of subjects experiencing a first event of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke (a composite cardiovascular outcome) is presented.

Secondary Outcome Measures

Time From Rand. to First Occurrence of an Expanded Composite Cardiovascular Outcome Defined as Either Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke, Revascularisation, Hospitalisation for Unstable Angina or for Heart Failure.

Time from randomisation to first occurrence of an expanded composite cardiovascular outcome defined as either cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularisation, hospitalisation for unstable angina or for heart failure. The percentage of subjects experiencing first occurrence of an expanded composite cardiovascular outcome defined as either cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularisation, hospitalisation for unstable angina or for heart failure is presented.

Time From Randomisation to All Cause Death

Time from randomisation to all cause death. The percentage of subjects with a death by any cause (all-cause death) is presented.

Time From Randomisation to Each Individual Component of the Expanded Composite Cardiovascular Outcome

Time from randomisation to each individual component of the expanded composite cardiovascular outcome. The percentage of subjects experiencing each of the individual component of the expanded composite cardiovascular outcome (defined as either cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularisation, hospitalisation for unstable angina or heart failure) is presented.

Time From Randomisation to First Occurrence of a Composite Microvascular Outcome

Time from randomisation to first occurrence of a composite microvascular outcome, defined as any one of the following: new onset of persistent macroalbuminuria persistent doubling of serum creatinine need for continuous renal replacement therapy death due to renal disease need for retinal photocoagulation or treatment with intravitreal agents vitreous haemorrhage diabetes-related blindness The percentage of subjects experiencing a first occurrence of a composite microvascular outcome is presented.

Time From Randomisation to Each Individual Component of the Composite Microvascular Outcome and to the Retinopathy and Nephropathy Composite Outcomes Separately.

Time from randomisation to each individual component of the composite microvascular outcome and to the retinopathy and nephropathy composite outcomes separately. The percentage of subjects experiencing each individual component of the composite microvascular outcome are presented.

Full Information

NCT ID

NCT01179048

First Posted

August 6, 2010

Last Updated

July 3, 2019

Sponsor

Novo Nordisk A/S

1. Study Identification

Unique Protocol Identification Number

NCT01179048

Brief Title

Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results

Acronym

LEADER®

Official Title

A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events

Study Type

Interventional

2. Study Status

Record Verification Date

July 2019

Overall Recruitment Status

Completed

Study Start Date

August 31, 2010 (Actual)

Primary Completion Date

December 17, 2015 (Actual)

Study Completion Date

December 17, 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Novo Nordisk A/S

4. Oversight

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

This trial is conducted in Africa, Asia, Europe, and North and South America. The aim of this trial is to determine the long term effect of liraglutide on cardiovascular events in subjects with type 2 diabetes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Diabetes, Diabetes Mellitus, Type 2

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 3

Interventional Study Model

Parallel Assignment

Masking

ParticipantInvestigator

Allocation

Randomized

Enrollment

9341 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Liraglutide

Arm Type

Experimental

Arm Title

Placebo

Arm Type

Placebo Comparator

Intervention Type

Drug

Intervention Name(s)

liraglutide

Intervention Description

Maximum dose of 1.8 mg liraglutide, injected subcutaneously (under the skin) once daily. Administered in addition to the subject's standard treatment

Intervention Type

Drug

Intervention Name(s)

placebo

Intervention Description

Maximum dose of 1.8 mg placebo, injected subcutaneously (under the skin) once daily. Administered in addition to the subject's standard treatment

Primary Outcome Measure Information:

Title

Time From Randomisation to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome)

Description

Time Frame

from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)

Secondary Outcome Measure Information:

Title

Description

Time Frame

from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)

Title

Time From Randomisation to All Cause Death

Description

Time from randomisation to all cause death. The percentage of subjects with a death by any cause (all-cause death) is presented.

Time Frame

from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)

Title

Time From Randomisation to Each Individual Component of the Expanded Composite Cardiovascular Outcome

Description

Time Frame

from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)

Title

Time From Randomisation to First Occurrence of a Composite Microvascular Outcome

Description

Time Frame

from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)

Title

Time From Randomisation to Each Individual Component of the Composite Microvascular Outcome and to the Retinopathy and Nephropathy Composite Outcomes Separately.

Description

Time Frame

from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)

10. Eligibility

Sex

All

Minimum Age & Unit of Time

50 Years

Accepts Healthy Volunteers

Eligibility Criteria

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Global Clinical Registry (GCR, 1452)

Organizational Affiliation

Novo Nordisk A/S

Official's Role

Study Director

Facility Information:

Facility Name

Novo Nordisk Investigational Site

City

Alabaster

State/Province

Alabama

ZIP/Postal Code

35007

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Birmingham

State/Province

Alabama

ZIP/Postal Code

35209

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Birmingham

State/Province

Alabama

ZIP/Postal Code

35294

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Huntsville

State/Province

Alabama

ZIP/Postal Code

35801

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Mobile

State/Province

Alabama

ZIP/Postal Code

36608

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Tempe

State/Province

Arizona

ZIP/Postal Code

85283

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Little Rock

State/Province

Arkansas

ZIP/Postal Code

72205-5446

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Little Rock

State/Province

Arkansas

ZIP/Postal Code

72205

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Anaheim

State/Province

California

ZIP/Postal Code

92801

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Cerritos

State/Province

California

ZIP/Postal Code

90703-2115

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Escondido

State/Province

California

ZIP/Postal Code

92025

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Fresno

State/Province

California

ZIP/Postal Code

93721-1443

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Los Angeles

State/Province

California

ZIP/Postal Code

90017-4006

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Los Banos

State/Province

California

ZIP/Postal Code

93635

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Mission Hills

State/Province

California

ZIP/Postal Code

91345

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Montclair

State/Province

California

ZIP/Postal Code

91763

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

San Diego

State/Province

California

ZIP/Postal Code

92111

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Tustin

State/Province

California

ZIP/Postal Code

92780

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Walnut Creek

State/Province

California

ZIP/Postal Code

94598

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Watsonville

State/Province

California

ZIP/Postal Code

95076

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Aurora

State/Province

Colorado

ZIP/Postal Code

80045-7402

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Denver

State/Province

Colorado

ZIP/Postal Code

80220

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Newark

State/Province

Delaware

ZIP/Postal Code

19713

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Bradenton

State/Province

Florida

ZIP/Postal Code

34201

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Clearwater

State/Province

Florida

ZIP/Postal Code

33756

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

DeLand

State/Province

Florida

ZIP/Postal Code

32724

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Fort Lauderdale

State/Province

Florida

ZIP/Postal Code

33316

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Kissimmee

State/Province

Florida

ZIP/Postal Code

34744

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Miami

State/Province

Florida

ZIP/Postal Code

33136

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Orlando

State/Province

Florida

ZIP/Postal Code

32804

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Saint Petersburg

State/Province

Florida

ZIP/Postal Code

33711

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Tampa

State/Province

Florida

ZIP/Postal Code

33624

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

West Palm Beach

State/Province

Florida

ZIP/Postal Code

33409

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Lawrenceville

State/Province

Georgia

ZIP/Postal Code

30046

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Roswell

State/Province

Georgia

ZIP/Postal Code

30076

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Chicago

State/Province

Illinois

ZIP/Postal Code

60607

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Chicago

State/Province

Illinois

ZIP/Postal Code

60612

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Chicago

State/Province

Illinois

ZIP/Postal Code

60654

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Crystal Lake

State/Province

Illinois

ZIP/Postal Code

60012

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Indianapolis

State/Province

Indiana

ZIP/Postal Code

46260-1992

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Michigan City

State/Province

Indiana

ZIP/Postal Code

46360

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

West Des Moines

State/Province

Iowa

ZIP/Postal Code

50265

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Lexington

State/Province

Kentucky

ZIP/Postal Code

40502

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Louisville

State/Province

Kentucky

ZIP/Postal Code

40202

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Louisville

State/Province

Kentucky

ZIP/Postal Code

40206

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Metairie

State/Province

Louisiana

ZIP/Postal Code

70006-2930

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Monroe

State/Province

Louisiana

ZIP/Postal Code

71203

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Natchitoches

State/Province

Louisiana

ZIP/Postal Code

71457-5881

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

New Orleans

State/Province

Louisiana

ZIP/Postal Code

70112

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Baltimore

State/Province

Maryland

ZIP/Postal Code

21204

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Baltimore

State/Province

Maryland

ZIP/Postal Code

21218-2829

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Bloomfield Hills

State/Province

Michigan

ZIP/Postal Code

48302

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Dearborn

State/Province

Michigan

ZIP/Postal Code

48124

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Interlochen

State/Province

Michigan

ZIP/Postal Code

49643

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Troy

State/Province

Michigan

ZIP/Postal Code

48085-5524

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Minneapolis

State/Province

Minnesota

ZIP/Postal Code

55416

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Saint Louis

State/Province

Missouri

ZIP/Postal Code

63108

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Springfield

State/Province

Missouri

ZIP/Postal Code

65807

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Great Falls

State/Province

Montana

ZIP/Postal Code

59405

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Omaha

State/Province

Nebraska

ZIP/Postal Code

68105

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Lebanon

State/Province

New Hampshire

ZIP/Postal Code

03756

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Nashua

State/Province

New Hampshire

ZIP/Postal Code

03063

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Mine Hill

State/Province

New Jersey

ZIP/Postal Code

07803

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Neptune

State/Province

New Jersey

ZIP/Postal Code

07753-4859

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Albany

State/Province

New York

ZIP/Postal Code

12208

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Buffalo

State/Province

New York

ZIP/Postal Code

14221-7091

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

New York

State/Province

New York

ZIP/Postal Code

10032

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

New York

State/Province

New York

ZIP/Postal Code

10036

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

New York

State/Province

New York

ZIP/Postal Code

10065

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Smithtown

State/Province

New York

ZIP/Postal Code

11787

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Syracuse

State/Province

New York

ZIP/Postal Code

13210

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Westfield

State/Province

New York

ZIP/Postal Code

14787

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Asheville

State/Province

North Carolina

ZIP/Postal Code

28801

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Burlington

State/Province

North Carolina

ZIP/Postal Code

27215

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Chapel Hill

State/Province

North Carolina

ZIP/Postal Code

27517

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Greensboro

State/Province

North Carolina

ZIP/Postal Code

27401

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Greenville

State/Province

North Carolina

ZIP/Postal Code

27834

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Monroe

State/Province

North Carolina

ZIP/Postal Code

28110

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Mooresville

State/Province

North Carolina

ZIP/Postal Code

28117

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Morehead City

State/Province

North Carolina

ZIP/Postal Code

28557

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Whiteville

State/Province

North Carolina

ZIP/Postal Code

28472

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Cadiz

State/Province

Ohio

ZIP/Postal Code

43907

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Cincinnati

State/Province

Ohio

ZIP/Postal Code

45219

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Cincinnati

State/Province

Ohio

ZIP/Postal Code

45220-2213

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Cleveland

State/Province

Ohio

ZIP/Postal Code

44106

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Marion

State/Province

Ohio

ZIP/Postal Code

43302

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Middleburg Heights

State/Province

Ohio

ZIP/Postal Code

44310

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Oklahoma City

State/Province

Oklahoma

ZIP/Postal Code

73103

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Oklahoma City

State/Province

Oklahoma

ZIP/Postal Code

73104

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Altoona

State/Province

Pennsylvania

ZIP/Postal Code

16602

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Beaver

State/Province

Pennsylvania

ZIP/Postal Code

15009-1957

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Hatfield

State/Province

Pennsylvania

ZIP/Postal Code

19440

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Philadelphia

State/Province

Pennsylvania

ZIP/Postal Code

19104

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Philadelphia

State/Province

Pennsylvania

ZIP/Postal Code

19107

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Pittsburgh

State/Province

Pennsylvania

ZIP/Postal Code

15243

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Uniontown

State/Province

Pennsylvania

ZIP/Postal Code

15401

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Charleston

State/Province

South Carolina

ZIP/Postal Code

29455

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Columbia

State/Province

South Carolina

ZIP/Postal Code

29203

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Greenville

State/Province

South Carolina

ZIP/Postal Code

29607

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Greer

State/Province

South Carolina

ZIP/Postal Code

29651

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Murrells Inlet

State/Province

South Carolina

ZIP/Postal Code

29576

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Myrtle Beach

State/Province

South Carolina

ZIP/Postal Code

29572

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Bartlett

State/Province

Tennessee

ZIP/Postal Code

38133

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Kingsport

State/Province

Tennessee

ZIP/Postal Code

37660

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Memphis

State/Province

Tennessee

ZIP/Postal Code

38163

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Nashville

State/Province

Tennessee

ZIP/Postal Code

37212

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Arlington

State/Province

Texas

ZIP/Postal Code

76014

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Corpus Christi

State/Province

Texas

ZIP/Postal Code

78404

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Dallas

State/Province

Texas

ZIP/Postal Code

75230

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Dallas

State/Province

Texas

ZIP/Postal Code

75231

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Dallas

State/Province

Texas

ZIP/Postal Code

75246

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Dallas

State/Province

Texas

ZIP/Postal Code

75390

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Houston

State/Province

Texas

ZIP/Postal Code

77070

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Houston

State/Province

Texas

ZIP/Postal Code

77095

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Longview

State/Province

Texas

ZIP/Postal Code

75605

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Lubbock

State/Province

Texas

ZIP/Postal Code

79423

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Odessa

State/Province

Texas

ZIP/Postal Code

79761

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

San Antonio

State/Province

Texas

ZIP/Postal Code

78228-3419

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

San Antonio

State/Province

Texas

ZIP/Postal Code

78229

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Schertz

State/Province

Texas

ZIP/Postal Code

78154

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Tomball

State/Province

Texas

ZIP/Postal Code

77375

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Salt Lake City

State/Province

Utah

ZIP/Postal Code

84102

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

South Burlington

State/Province

Vermont

ZIP/Postal Code

05403

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Spokane

State/Province

Washington

ZIP/Postal Code

99210

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Madison

State/Province

Wisconsin

ZIP/Postal Code

53717

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Blacktown

State/Province

New South Wales

ZIP/Postal Code

2148

Country

Australia

Facility Name

Novo Nordisk Investigational Site

City

Douglas

State/Province

Queensland

ZIP/Postal Code

4814

Country

Australia

Facility Name

Novo Nordisk Investigational Site

City

Herston

State/Province

Queensland

ZIP/Postal Code

4029

Country

Australia

Facility Name

Novo Nordisk Investigational Site

City

Meadowbrook

State/Province

Queensland

ZIP/Postal Code

4131

Country

Australia

Facility Name

Novo Nordisk Investigational Site

City

Keswick

State/Province

South Australia

ZIP/Postal Code

5035

Country

Australia

Facility Name

Novo Nordisk Investigational Site

City

Oaklands Park

State/Province

South Australia

ZIP/Postal Code

5046

Country

Australia

Facility Name

Novo Nordisk Investigational Site

City

Hobart

State/Province

Tasmania

ZIP/Postal Code

7000

Country

Australia

Facility Name

Novo Nordisk Investigational Site

City

Box Hill

State/Province

Victoria

ZIP/Postal Code

3128

Country

Australia

Facility Name

Novo Nordisk Investigational Site

City

Fitzroy

State/Province

Victoria

ZIP/Postal Code

3065

Country

Australia

Facility Name

Novo Nordisk Investigational Site

City

Fremantle

State/Province

Western Australia

ZIP/Postal Code

6160

Country

Australia

Facility Name

Novo Nordisk Investigational Site

City

Graz

ZIP/Postal Code

8036

Country

Austria

Facility Name

Novo Nordisk Investigational Site

City

Wien

ZIP/Postal Code

1030

Country

Austria

Facility Name

Novo Nordisk Investigational Site

City

Wien

ZIP/Postal Code

1090

Country

Austria

Facility Name

Novo Nordisk Investigational Site

City

Wien

ZIP/Postal Code

1130

Country

Austria

Facility Name

Novo Nordisk Investigational Site

City

Wien

ZIP/Postal Code

1140

Country

Austria

Facility Name

Novo Nordisk Investigational Site

City

Edegem

ZIP/Postal Code

2650

Country

Belgium

Facility Name

Novo Nordisk Investigational Site

City

Gent

ZIP/Postal Code

9000

Country

Belgium

Facility Name

Novo Nordisk Investigational Site

City

Leuven

ZIP/Postal Code

3000

Country

Belgium

Facility Name

Novo Nordisk Investigational Site

City

Liège

ZIP/Postal Code

4000

Country

Belgium

Facility Name

Novo Nordisk Investigational Site

City

Fortaleza

State/Province

Ceara

ZIP/Postal Code

60115-282

Country

Brazil

Facility Name

Novo Nordisk Investigational Site

City

Fortaleza

State/Province

Ceara

ZIP/Postal Code

60170-001

Country

Brazil

Facility Name

Novo Nordisk Investigational Site

City

Fortaleza

State/Province

Ceara

ZIP/Postal Code

60192-340

Country

Brazil

Facility Name

Novo Nordisk Investigational Site

City

Aparecida de Goiania

State/Province

Goias

ZIP/Postal Code

74935-530

Country

Brazil

Facility Name

Novo Nordisk Investigational Site

City

Curitiba

State/Province

Parana

ZIP/Postal Code

80010-030

Country

Brazil

Facility Name

Novo Nordisk Investigational Site

City

Curitiba

State/Province

Parana

ZIP/Postal Code

80030-110

Country

Brazil

Facility Name

Novo Nordisk Investigational Site

City

Curitiba

State/Province

Parana

ZIP/Postal Code

80810-040

Country

Brazil

Facility Name

Novo Nordisk Investigational Site

City

Belém

State/Province

Para

ZIP/Postal Code

66073-000

Country

Brazil

Facility Name

Novo Nordisk Investigational Site

City

Caxias Do Sul

State/Province

Rio Grande Do Sul

ZIP/Postal Code

95070-560

Country

Brazil

Facility Name

Novo Nordisk Investigational Site

City

Porto Alegre

State/Province

Rio Grande Do Sul

ZIP/Postal Code

90035-001

Country

Brazil

Facility Name

Novo Nordisk Investigational Site

City

Campinas

State/Province

Sao Paulo

ZIP/Postal Code

13059-740

Country

Brazil

Facility Name

Novo Nordisk Investigational Site

City

Campinas

State/Province

Sao Paulo

ZIP/Postal Code

13073-350

Country

Brazil

Facility Name

Novo Nordisk Investigational Site

City

Mogi das Cruzes

State/Province

Sao Paulo

ZIP/Postal Code

08780-090

Country

Brazil

Facility Name

Novo Nordisk Investigational Site

City

São Paulo

State/Province

Sao Paulo

ZIP/Postal Code

01223-001

Country

Brazil

Facility Name

Novo Nordisk Investigational Site

City

São Paulo

State/Province

Sao Paulo

ZIP/Postal Code

01228-000

Country

Brazil

Facility Name

Novo Nordisk Investigational Site

City

São Paulo

State/Province

Sao Paulo

ZIP/Postal Code

01228-200

Country

Brazil

Facility Name

Novo Nordisk Investigational Site

City

São Paulo

State/Province

Sao Paulo

ZIP/Postal Code

04012-909

Country

Brazil

Facility Name

Novo Nordisk Investigational Site

City

São Paulo

State/Province

Sao Paulo

ZIP/Postal Code

04020-041

Country

Brazil

Facility Name

Novo Nordisk Investigational Site

City

São Paulo

State/Province

Sao Paulo

ZIP/Postal Code

05403-000

Country

Brazil

Facility Name

Novo Nordisk Investigational Site

City

Aracajú

ZIP/Postal Code

49020-270

Country

Brazil

Facility Name

Novo Nordisk Investigational Site

City

Belo Horizonte

ZIP/Postal Code

30150-221

Country

Brazil

Facility Name

Novo Nordisk Investigational Site

City

Campinas

ZIP/Postal Code

13084-971

Country

Brazil

Facility Name

Novo Nordisk Investigational Site

City

Curitiba

ZIP/Postal Code

80420-011

Country

Brazil

Facility Name

Novo Nordisk Investigational Site

City

Fortaleza

ZIP/Postal Code

60430-350

Country

Brazil

Facility Name

Novo Nordisk Investigational Site

City

Goiânia

ZIP/Postal Code

74110-120

Country

Brazil

Facility Name

Novo Nordisk Investigational Site

City

Joinville

ZIP/Postal Code

05001-100

Country

Brazil

Facility Name

Novo Nordisk Investigational Site

City

Marília

ZIP/Postal Code

17519-000

Country

Brazil

Facility Name

Novo Nordisk Investigational Site

City

Porto Alegre

ZIP/Postal Code

90035-170

Country

Brazil

Facility Name

Novo Nordisk Investigational Site

City

Recife

ZIP/Postal Code

52020-010

Country

Brazil

Facility Name

Novo Nordisk Investigational Site

City

Rio de Janeiro

ZIP/Postal Code

20211-340

Country

Brazil

Facility Name

Novo Nordisk Investigational Site

City

Rio de Janeiro

ZIP/Postal Code

20551-030

Country

Brazil

Facility Name

Novo Nordisk Investigational Site

City

Santos

ZIP/Postal Code

11045-904

Country

Brazil

Facility Name

Novo Nordisk Investigational Site

City

Sao Paulo

ZIP/Postal Code

01323-001

Country

Brazil

Facility Name

Novo Nordisk Investigational Site

City

Sao Paulo

ZIP/Postal Code

04011-030

Country

Brazil

Facility Name

Novo Nordisk Investigational Site

City

São Paulo

ZIP/Postal Code

05403-000

Country

Brazil

Facility Name

Novo Nordisk Investigational Site

City

Edmonton

State/Province

Alberta

ZIP/Postal Code

T5J 3N4

Country

Canada

Facility Name

Novo Nordisk Investigational Site

City

Vancouver

State/Province

British Columbia

ZIP/Postal Code

V6H 3X8

Country

Canada

Facility Name

Novo Nordisk Investigational Site

City

Winnipeg

State/Province

Manitoba

ZIP/Postal Code

R3E 3P4

Country

Canada

Facility Name

Novo Nordisk Investigational Site

City

St.John's

State/Province

Newfoundland and Labrador

ZIP/Postal Code

A1B 3V6

Country

Canada

Facility Name

Novo Nordisk Investigational Site

City

Halifax

State/Province

Nova Scotia

ZIP/Postal Code

B3H 2Y9

Country

Canada

Facility Name

Novo Nordisk Investigational Site

City

Cambridge

State/Province

Ontario

ZIP/Postal Code

N1R 7L6

Country

Canada

Facility Name

Novo Nordisk Investigational Site

City

Cornwall

State/Province

Ontario

ZIP/Postal Code

K6H 4M4

Country

Canada

Facility Name

Novo Nordisk Investigational Site

City

London

State/Province

Ontario

ZIP/Postal Code

N6A 4V2

Country

Canada

Facility Name

Novo Nordisk Investigational Site

City

London

State/Province

Ontario

ZIP/Postal Code

N6G 2M1

Country

Canada

Facility Name

Novo Nordisk Investigational Site

City

Mississauga

State/Province

Ontario

ZIP/Postal Code

L5M 2V8

Country

Canada

Facility Name

Novo Nordisk Investigational Site

City

Scarborough

State/Province

Ontario

ZIP/Postal Code

M1E 5E9

Country

Canada

Facility Name

Novo Nordisk Investigational Site

City

Smiths Falls

State/Province

Ontario

ZIP/Postal Code

K7A 4W8

Country

Canada

Facility Name

Novo Nordisk Investigational Site

City

Thunder Bay

State/Province

Ontario

ZIP/Postal Code

P7A 4V7

Country

Canada

Facility Name

Novo Nordisk Investigational Site

City

Toronto

State/Province

Ontario

ZIP/Postal Code

M5C 2T2

Country

Canada

Facility Name

Novo Nordisk Investigational Site

City

Toronto

State/Province

Ontario

ZIP/Postal Code

M5T 3L9

Country

Canada

Facility Name

Novo Nordisk Investigational Site

City

Montreal

State/Province

Quebec

ZIP/Postal Code

H2W 1R7

Country

Canada

Facility Name

Novo Nordisk Investigational Site

City

Quebec

ZIP/Postal Code

G1V 4G2

Country

Canada

Facility Name

Novo Nordisk Investigational Site

City

Quebec

ZIP/Postal Code

G1V 4G5

Country

Canada

Facility Name

Novo Nordisk Investigational Site

City

Beijing

State/Province

Beijing

ZIP/Postal Code

100044

Country

China

Facility Name

Novo Nordisk Investigational Site

City

Beijing

State/Province

Beijing

ZIP/Postal Code

100730

Country

China

Facility Name

Novo Nordisk Investigational Site

City

Beijing

State/Province

Beijing

ZIP/Postal Code

100853

Country

China

Facility Name

Novo Nordisk Investigational Site

City

Xiamen

State/Province

Fujian

ZIP/Postal Code

361003

Country

China

Facility Name

Novo Nordisk Investigational Site

City

Guangzhou

State/Province

Guangdong

ZIP/Postal Code

510120

Country

China

Facility Name

Novo Nordisk Investigational Site

City

Zhenjiang

State/Province

Jiangsu

ZIP/Postal Code

212001

Country

China

Facility Name

Novo Nordisk Investigational Site

City

Qingdao

State/Province

Shandong

ZIP/Postal Code

266003

Country

China

Facility Name

Novo Nordisk Investigational Site

City

Shanghai

State/Province

Shanghai

ZIP/Postal Code

200003

Country

China

Facility Name

Novo Nordisk Investigational Site

City

Plzen

ZIP/Postal Code

304 60

Country

Czechia

Facility Name

Novo Nordisk Investigational Site

City

Praha

ZIP/Postal Code

128 08

Country

Czechia

Facility Name

Novo Nordisk Investigational Site

City

Aalborg

ZIP/Postal Code

9100

Country

Denmark

Facility Name

Novo Nordisk Investigational Site

City

Esbjerg

ZIP/Postal Code

6700

Country

Denmark

Facility Name

Novo Nordisk Investigational Site

City

Gentofte

ZIP/Postal Code

2820

Country

Denmark

Facility Name

Novo Nordisk Investigational Site

City

Hvidovre

ZIP/Postal Code

2650

Country

Denmark

Facility Name

Novo Nordisk Investigational Site

City

Odense

ZIP/Postal Code

5000

Country

Denmark

Facility Name

Novo Nordisk Investigational Site

City

Århus C

ZIP/Postal Code

8000

Country

Denmark

Facility Name

Novo Nordisk Investigational Site

City

Kuopio

ZIP/Postal Code

70210

Country

Finland

Facility Name

Novo Nordisk Investigational Site

City

Lahti

ZIP/Postal Code

15110

Country

Finland

Facility Name

Novo Nordisk Investigational Site

City

Oulu

ZIP/Postal Code

90220

Country

Finland

Facility Name

Novo Nordisk Investigational Site

City

Tampere

ZIP/Postal Code

33520

Country

Finland

Facility Name

Novo Nordisk Investigational Site

City

Vantaa

ZIP/Postal Code

FIN-01600

Country

Finland

Facility Name

Novo Nordisk Investigational Site

City

Corbeil Essonnes

ZIP/Postal Code

91106

Country

France

Facility Name

Novo Nordisk Investigational Site

City

Jarny

ZIP/Postal Code

54800

Country

France

Facility Name

Novo Nordisk Investigational Site

City

Nimes

ZIP/Postal Code

30006

Country

France

Facility Name

Novo Nordisk Investigational Site

City

Paris

ZIP/Postal Code

75877

Country

France

Facility Name

Novo Nordisk Investigational Site

City

Angermünde/OT Wolletz

ZIP/Postal Code

16278

Country

Germany

Facility Name

Novo Nordisk Investigational Site

City

Aschaffenburg

ZIP/Postal Code

63739

Country

Germany

Facility Name

Novo Nordisk Investigational Site

City

Berlin

ZIP/Postal Code

12163

Country

Germany

Facility Name

Novo Nordisk Investigational Site

City

Berlin

ZIP/Postal Code

13055

Country

Germany

Facility Name

Novo Nordisk Investigational Site

City

Dillingen

ZIP/Postal Code

89407

Country

Germany

Facility Name

Novo Nordisk Investigational Site

City

Dresden

ZIP/Postal Code

01219

Country

Germany

Facility Name

Novo Nordisk Investigational Site

City

Elsterwerda

ZIP/Postal Code

04910

Country

Germany

Facility Name

Novo Nordisk Investigational Site

City

Essen

ZIP/Postal Code

45219

Country

Germany

Facility Name

Novo Nordisk Investigational Site

City

Falkensee

ZIP/Postal Code

14612

Country

Germany

Facility Name

Novo Nordisk Investigational Site

City

Gifhorn

ZIP/Postal Code

38518

Country

Germany

Facility Name

Novo Nordisk Investigational Site

City

Hamburg

ZIP/Postal Code

22587

Country

Germany

Facility Name

Novo Nordisk Investigational Site

City

Karlsbad

ZIP/Postal Code

76307

Country

Germany

Facility Name

Novo Nordisk Investigational Site

City

Leipzig

ZIP/Postal Code

04103

Country

Germany

Facility Name

Novo Nordisk Investigational Site

City

Leipzig

ZIP/Postal Code

04275

Country

Germany

Facility Name

Novo Nordisk Investigational Site

City

Ludwigshafen

ZIP/Postal Code

67059

Country

Germany

Facility Name

Novo Nordisk Investigational Site

City

Mannheim

ZIP/Postal Code

68163

Country

Germany

Facility Name

Novo Nordisk Investigational Site

City

München

ZIP/Postal Code

80336

Country

Germany

Facility Name

Novo Nordisk Investigational Site

City

Oldenburg

ZIP/Postal Code

23758

Country

Germany

Facility Name

Novo Nordisk Investigational Site

City

Saint Ingbert-Oberwürzbach

ZIP/Postal Code

66386

Country

Germany

Facility Name

Novo Nordisk Investigational Site

City

Schkeuditz

ZIP/Postal Code

04435

Country

Germany

Facility Name

Novo Nordisk Investigational Site

City

Schweinfurt

ZIP/Postal Code

97421

Country

Germany

Facility Name

Novo Nordisk Investigational Site

City

Ulm

ZIP/Postal Code

89081

Country

Germany

Facility Name

Novo Nordisk Investigational Site

City

Villingen-Schwenningen

ZIP/Postal Code

78048

Country

Germany

Facility Name

Novo Nordisk Investigational Site

City

Wangen

ZIP/Postal Code

88239

Country

Germany

Facility Name

Novo Nordisk Investigational Site

City

Athens

ZIP/Postal Code

GR-10552

Country

Greece

Facility Name

Novo Nordisk Investigational Site

City

Athens

ZIP/Postal Code

GR-11527

Country

Greece

Facility Name

Novo Nordisk Investigational Site

City

Crete

ZIP/Postal Code

71001

Country

Greece

Facility Name

Novo Nordisk Investigational Site

City

Thessaloniki

ZIP/Postal Code

GR-57001

Country

Greece

Facility Name

Novo Nordisk Investigational Site

City

Hyderabad

State/Province

Andhra Pradesh

ZIP/Postal Code

500034

Country

India

Facility Name

Novo Nordisk Investigational Site

City

Hyderbad

State/Province

Andhra Pradesh

ZIP/Postal Code

500 012

Country

India

Facility Name

Novo Nordisk Investigational Site

City

Guwahati

State/Province

Assam

ZIP/Postal Code

781007

Country

India

Facility Name

Novo Nordisk Investigational Site

City

Karnal

State/Province

Haryana

ZIP/Postal Code

132001

Country

India

Facility Name

Novo Nordisk Investigational Site

City

Bangalore

State/Province

Karnataka

ZIP/Postal Code

560 003

Country

India

Facility Name

Novo Nordisk Investigational Site

City

Bangalore

State/Province

Karnataka

ZIP/Postal Code

560043

Country

India

Facility Name

Novo Nordisk Investigational Site

City

Bangalore

State/Province

Karnataka

ZIP/Postal Code

560052

Country

India

Facility Name

Novo Nordisk Investigational Site

City

Manipal

State/Province

Karnataka

ZIP/Postal Code

576104

Country

India

Facility Name

Novo Nordisk Investigational Site

City

Kochi

State/Province

Kerala

ZIP/Postal Code

682041

Country

India

Facility Name

Novo Nordisk Investigational Site

City

Indore

State/Province

Madhya Pradesh

ZIP/Postal Code

452010

Country

India

Facility Name

Novo Nordisk Investigational Site

City

Mumbai

State/Province

Maharashtra

ZIP/Postal Code

400012

Country

India

Facility Name

Novo Nordisk Investigational Site

City

Chandigarh

State/Province

Punjab

ZIP/Postal Code

160012

Country

India

Facility Name

Novo Nordisk Investigational Site

City

Chennai

State/Province

Tamil Nadu

ZIP/Postal Code

600029

Country

India

Facility Name

Novo Nordisk Investigational Site

City

Chennai

State/Province

Tamil Nadu

ZIP/Postal Code

600086

Country

India

Facility Name

Novo Nordisk Investigational Site

City

Madurai

State/Province

Tamil Nadu

ZIP/Postal Code

625 020

Country

India

Facility Name

Novo Nordisk Investigational Site

City

Vellore

State/Province

Tamil Nadu

ZIP/Postal Code

632004

Country

India

Facility Name

Novo Nordisk Investigational Site

City

Kolkata

State/Province

West Bengal

ZIP/Postal Code

700054

Country

India

Facility Name

Novo Nordisk Investigational Site

City

Thriruvananthapuram

ZIP/Postal Code

695 032

Country

India

Facility Name

Novo Nordisk Investigational Site

City

Dublin 9

Country

Ireland

Facility Name

Novo Nordisk Investigational Site

City

Dublin

ZIP/Postal Code

DUBLIN 4

Country

Ireland

Facility Name

Novo Nordisk Investigational Site

City

Haifa

ZIP/Postal Code

31096

Country

Israel

Facility Name

Novo Nordisk Investigational Site

City

Haifa

ZIP/Postal Code

35152

Country

Israel

Facility Name

Novo Nordisk Investigational Site

City

Jerusalem

ZIP/Postal Code

91120

Country

Israel

Facility Name

Novo Nordisk Investigational Site

City

Petah-Tikva

ZIP/Postal Code

49372

Country

Israel

Facility Name

Novo Nordisk Investigational Site

City

Tel Hashomer

ZIP/Postal Code

52621

Country

Israel

Facility Name

Novo Nordisk Investigational Site

City

Bologna

ZIP/Postal Code

40138

Country

Italy

Facility Name

Novo Nordisk Investigational Site

City

Catanzaro

ZIP/Postal Code

88100

Country

Italy

Facility Name

Novo Nordisk Investigational Site

City

Chieti

ZIP/Postal Code

66100

Country

Italy

Facility Name

Novo Nordisk Investigational Site

City

Firenze

ZIP/Postal Code

50141

Country

Italy

Facility Name

Novo Nordisk Investigational Site

City

Latina

ZIP/Postal Code

04100

Country

Italy

Facility Name

Novo Nordisk Investigational Site

City

Lucca

ZIP/Postal Code

55100

Country

Italy

Facility Name

Novo Nordisk Investigational Site

City

Milano

ZIP/Postal Code

20132

Country

Italy

Facility Name

Novo Nordisk Investigational Site

City

Padova

ZIP/Postal Code

35128

Country

Italy

Facility Name

Novo Nordisk Investigational Site

City

Palermo

ZIP/Postal Code

90127

Country

Italy

Facility Name

Novo Nordisk Investigational Site

City

Roma

ZIP/Postal Code

00133

Country

Italy

Facility Name

Novo Nordisk Investigational Site

City

Roma

ZIP/Postal Code

00161

Country

Italy

Facility Name

Novo Nordisk Investigational Site

City

Goyang

ZIP/Postal Code

410-719

Country

Korea, Republic of

Facility Name

Novo Nordisk Investigational Site

City

Seongnam-si

ZIP/Postal Code

463-707

Country

Korea, Republic of

Facility Name

Novo Nordisk Investigational Site

City

Seoul

ZIP/Postal Code

02447

Country

Korea, Republic of

Facility Name

Novo Nordisk Investigational Site

City

Seoul

ZIP/Postal Code

137-701

Country

Korea, Republic of

Facility Name

Novo Nordisk Investigational Site

City

Seoul

ZIP/Postal Code

139-827

Country

Korea, Republic of

Facility Name

Novo Nordisk Investigational Site

City

Tijuana

State/Province

Baja California Norte

ZIP/Postal Code

22010

Country

Mexico

Facility Name

Novo Nordisk Investigational Site

City

Guadalajara

State/Province

Jalisco

ZIP/Postal Code

44600

Country

Mexico

Facility Name

Novo Nordisk Investigational Site

City

Guadalajara

State/Province

Jalisco

ZIP/Postal Code

44650

Country

Mexico

Facility Name

Novo Nordisk Investigational Site

City

Aguascalientes

ZIP/Postal Code

20230

Country

Mexico

Facility Name

Novo Nordisk Investigational Site

City

Durango

ZIP/Postal Code

34000

Country

Mexico

Facility Name

Novo Nordisk Investigational Site

City

Durango

ZIP/Postal Code

34080

Country

Mexico

Facility Name

Novo Nordisk Investigational Site

City

Monterrey

ZIP/Postal Code

64460

Country

Mexico

Facility Name

Novo Nordisk Investigational Site

City

San Luis Potosi

ZIP/Postal Code

78200

Country

Mexico

Facility Name

Novo Nordisk Investigational Site

City

Amsterdam

ZIP/Postal Code

1066 EC

Country

Netherlands

Facility Name

Novo Nordisk Investigational Site

City

Eindhoven

ZIP/Postal Code

5631 BM

Country

Netherlands

Facility Name

Novo Nordisk Investigational Site

City

Etten-Leur

ZIP/Postal Code

4872 LP

Country

Netherlands

Facility Name

Novo Nordisk Investigational Site

City

Goes

ZIP/Postal Code

4461 LT

Country

Netherlands

Facility Name

Novo Nordisk Investigational Site

City

Groningen

ZIP/Postal Code

9728 NT

Country

Netherlands

Facility Name

Novo Nordisk Investigational Site

City

Hoogeveen

ZIP/Postal Code

7909 AA

Country

Netherlands

Facility Name

Novo Nordisk Investigational Site

City

Maastricht

ZIP/Postal Code

6229 HX

Country

Netherlands

Facility Name

Novo Nordisk Investigational Site

City

Nijmegen

ZIP/Postal Code

6525 GA

Country

Netherlands

Facility Name

Novo Nordisk Investigational Site

City

Utrecht

ZIP/Postal Code

3584 CX

Country

Netherlands

Facility Name

Novo Nordisk Investigational Site

City

Oslo

ZIP/Postal Code

0407

Country

Norway

Facility Name

Novo Nordisk Investigational Site

City

Oslo

ZIP/Postal Code

0586

Country

Norway

Facility Name

Novo Nordisk Investigational Site

City

Stavanger

ZIP/Postal Code

4011

Country

Norway

Facility Name

Novo Nordisk Investigational Site

City

Trondheim

ZIP/Postal Code

7030

Country

Norway

Facility Name

Novo Nordisk Investigational Site

City

Tønsberg

ZIP/Postal Code

3117

Country

Norway

Facility Name

Novo Nordisk Investigational Site

City

Bialystok

ZIP/Postal Code

15-435

Country

Poland

Facility Name

Novo Nordisk Investigational Site

City

Bydgoszcz

ZIP/Postal Code

85-822

Country

Poland

Facility Name

Novo Nordisk Investigational Site

City

Katowice

ZIP/Postal Code

40-084

Country

Poland

Facility Name

Novo Nordisk Investigational Site

City

Krakow

ZIP/Postal Code

31-261

Country

Poland

Facility Name

Novo Nordisk Investigational Site

City

Krakow

ZIP/Postal Code

31-271

Country

Poland

Facility Name

Novo Nordisk Investigational Site

City

Krakow

ZIP/Postal Code

31-501

Country

Poland

Facility Name

Novo Nordisk Investigational Site

City

Lodz

ZIP/Postal Code

93-338

Country

Poland

Facility Name

Novo Nordisk Investigational Site

City

Poznan

ZIP/Postal Code

60-569

Country

Poland

Facility Name

Novo Nordisk Investigational Site

City

Pulawy

ZIP/Postal Code

24-100

Country

Poland

Facility Name

Novo Nordisk Investigational Site

City

Ruda Slaska

ZIP/Postal Code

41-709

Country

Poland

Facility Name

Novo Nordisk Investigational Site

City

Warszawa

ZIP/Postal Code

01-192

Country

Poland

Facility Name

Novo Nordisk Investigational Site

City

Warszawa

ZIP/Postal Code

02-507

Country

Poland

Facility Name

Novo Nordisk Investigational Site

City

Wroclaw

ZIP/Postal Code

50-381

Country

Poland

Facility Name

Novo Nordisk Investigational Site

City

Bayamon

ZIP/Postal Code

00961

Country

Puerto Rico

Facility Name

Novo Nordisk Investigational Site

City

Caguas

ZIP/Postal Code

00725

Country

Puerto Rico

Facility Name

Novo Nordisk Investigational Site

City

Craiova

State/Province

Dolj

ZIP/Postal Code

200642

Country

Romania

Facility Name

Novo Nordisk Investigational Site

City

Targu Mures

State/Province

Mures

ZIP/Postal Code

540098

Country

Romania

Facility Name

Novo Nordisk Investigational Site

City

Timisoara

State/Province

Timis

ZIP/Postal Code

300736

Country

Romania

Facility Name

Novo Nordisk Investigational Site

City

Bacau

ZIP/Postal Code

600114

Country

Romania

Facility Name

Novo Nordisk Investigational Site

City

Bucharest

ZIP/Postal Code

020475

Country

Romania

Facility Name

Novo Nordisk Investigational Site

City

Constanta

ZIP/Postal Code

900591

Country

Romania

Facility Name

Novo Nordisk Investigational Site

City

Deva

ZIP/Postal Code

330084

Country

Romania

Facility Name

Novo Nordisk Investigational Site

City

Iasi

ZIP/Postal Code

700547

Country

Romania

Facility Name

Novo Nordisk Investigational Site

City

Satu Mare

ZIP/Postal Code

440055

Country

Romania

Facility Name

Novo Nordisk Investigational Site

City

Sibiu

ZIP/Postal Code

550245

Country

Romania

Facility Name

Novo Nordisk Investigational Site

City

Arkhangelsk

ZIP/Postal Code

163001

Country

Russian Federation

Facility Name

Novo Nordisk Investigational Site

City

Arkhangelsk

ZIP/Postal Code

163045

Country

Russian Federation

Facility Name

Novo Nordisk Investigational Site

City

Barnaul

ZIP/Postal Code

656045

Country

Russian Federation

Facility Name

Novo Nordisk Investigational Site

City

Kazan

ZIP/Postal Code

420043

Country

Russian Federation

Facility Name

Novo Nordisk Investigational Site

City

Moscow

ZIP/Postal Code

117036

Country

Russian Federation

Facility Name

Novo Nordisk Investigational Site

City

Moscow

ZIP/Postal Code

119435

Country

Russian Federation

Facility Name

Novo Nordisk Investigational Site

City

Moscow

ZIP/Postal Code

125367

Country

Russian Federation

Facility Name

Novo Nordisk Investigational Site

City

Moscow

ZIP/Postal Code

127486

Country

Russian Federation

Facility Name

Novo Nordisk Investigational Site

City

Nizhniy Novgorod

ZIP/Postal Code

603126

Country

Russian Federation

Facility Name

Novo Nordisk Investigational Site

City

Penza

ZIP/Postal Code

440026

Country

Russian Federation

Facility Name

Novo Nordisk Investigational Site

City

Saratov

ZIP/Postal Code

410053

Country

Russian Federation

Facility Name

Novo Nordisk Investigational Site

City

Smolensk

ZIP/Postal Code

214019

Country

Russian Federation

Facility Name

Novo Nordisk Investigational Site

City

Tumen

ZIP/Postal Code

625023

Country

Russian Federation

Facility Name

Novo Nordisk Investigational Site

City

Yaroslavl

ZIP/Postal Code

150062

Country

Russian Federation

Facility Name

Novo Nordisk Investigational Site

City

Belgrade

ZIP/Postal Code

11000

Country

Serbia

Facility Name

Novo Nordisk Investigational Site

City

Bloemfontein

State/Province

Free State

ZIP/Postal Code

9301

Country

South Africa

Facility Name

Novo Nordisk Investigational Site

City

Johannesburg

State/Province

Gauteng

ZIP/Postal Code

1829

Country

South Africa

Facility Name

Novo Nordisk Investigational Site

City

Johannesburg

State/Province

Gauteng

ZIP/Postal Code

2013

Country

South Africa

Facility Name

Novo Nordisk Investigational Site

City

Lenasia

State/Province

Gauteng

ZIP/Postal Code

1827

Country

South Africa

Facility Name

Novo Nordisk Investigational Site

City

Midrand

State/Province

Gauteng

ZIP/Postal Code

1685

Country

South Africa

Facility Name

Novo Nordisk Investigational Site

City

Pretoria

State/Province

Gauteng

ZIP/Postal Code

0001

Country

South Africa

Facility Name

Novo Nordisk Investigational Site

City

Pretoria

State/Province

Gauteng

ZIP/Postal Code

0083

Country

South Africa

Facility Name

Novo Nordisk Investigational Site

City

Pretoria

State/Province

Gauteng

ZIP/Postal Code

0181

Country

South Africa

Facility Name

Novo Nordisk Investigational Site

City

Durban

State/Province

KwaZulu-Natal

ZIP/Postal Code

4091

Country

South Africa

Facility Name

Novo Nordisk Investigational Site

City

Durban

State/Province

KwaZulu-Natal

ZIP/Postal Code

4126

Country

South Africa

Facility Name

Novo Nordisk Investigational Site

City

Durban

State/Province

KwaZulu-Natal

ZIP/Postal Code

4320

Country

South Africa

Facility Name

Novo Nordisk Investigational Site

City

Tongaat

State/Province

KwaZulu-Natal

ZIP/Postal Code

4400

Country

South Africa

Facility Name

Novo Nordisk Investigational Site

City

Cape Town

State/Province

Western Cape

Country

South Africa

Facility Name

Novo Nordisk Investigational Site

City

Somerset West

State/Province

Western Cape

ZIP/Postal Code

7130

Country

South Africa

Facility Name

Novo Nordisk Investigational Site

City

Alberton

ZIP/Postal Code

1449

Country

South Africa

Facility Name

Novo Nordisk Investigational Site

City

Cape Town

ZIP/Postal Code

7530

Country

South Africa

Facility Name

Novo Nordisk Investigational Site

City

Almería

ZIP/Postal Code

04001

Country

Spain

Facility Name

Novo Nordisk Investigational Site

City

Barcelona

ZIP/Postal Code

08036

Country

Spain

Facility Name

Novo Nordisk Investigational Site

City

La Coruña

ZIP/Postal Code

15006

Country

Spain

Facility Name

Novo Nordisk Investigational Site

City

Madrid

ZIP/Postal Code

28040

Country

Spain

Facility Name

Novo Nordisk Investigational Site

City

Mora De Ebre

ZIP/Postal Code

43740

Country

Spain

Facility Name

Novo Nordisk Investigational Site

City

Mostoles - Madrid -

ZIP/Postal Code

28935

Country

Spain

Facility Name

Novo Nordisk Investigational Site

City

Palma de Mallorca

ZIP/Postal Code

07198

Country

Spain

Facility Name

Novo Nordisk Investigational Site

City

Pozuelo de Alarcon

ZIP/Postal Code

28223

Country

Spain

Facility Name

Novo Nordisk Investigational Site

City

Sevilla

ZIP/Postal Code

41003

Country

Spain

Facility Name

Novo Nordisk Investigational Site

City

Sevilla

ZIP/Postal Code

41014

Country

Spain

Facility Name

Novo Nordisk Investigational Site

City

Valladolid

ZIP/Postal Code

47005

Country

Spain

Facility Name

Novo Nordisk Investigational Site

City

Göteborg

ZIP/Postal Code

413 45

Country

Sweden

Facility Name

Novo Nordisk Investigational Site

City

Malmö

ZIP/Postal Code

205 02

Country

Sweden

Facility Name

Novo Nordisk Investigational Site

City

Stockholm

ZIP/Postal Code

111 57

Country

Sweden

Facility Name

Novo Nordisk Investigational Site

City

Stockholm

ZIP/Postal Code

113 24

Country

Sweden

Facility Name

Novo Nordisk Investigational Site

City

Stockholm

ZIP/Postal Code

141 86

Country

Sweden

Facility Name

Novo Nordisk Investigational Site

City

Örebro

ZIP/Postal Code

701 85

Country

Sweden

Facility Name

Novo Nordisk Investigational Site

City

Changhua City

ZIP/Postal Code

500

Country

Taiwan

Facility Name

Novo Nordisk Investigational Site

City

Kaoshiung

ZIP/Postal Code

807

Country

Taiwan

Facility Name

Novo Nordisk Investigational Site

City

Tainan city

ZIP/Postal Code

710

Country

Taiwan

Facility Name

Novo Nordisk Investigational Site

City

Taoyuan

ZIP/Postal Code

333

Country

Taiwan

Facility Name

Novo Nordisk Investigational Site

City

Ankara

ZIP/Postal Code

06100

Country

Turkey

Facility Name

Novo Nordisk Investigational Site

City

Ankara

ZIP/Postal Code

06500

Country

Turkey

Facility Name

Novo Nordisk Investigational Site

City

Antalya

ZIP/Postal Code

07058

Country

Turkey

Facility Name

Novo Nordisk Investigational Site

City

Bursa

ZIP/Postal Code

16059

Country

Turkey

Facility Name

Novo Nordisk Investigational Site

City

Gaziantep

ZIP/Postal Code

27070

Country

Turkey

Facility Name

Novo Nordisk Investigational Site

City

Istanbul

ZIP/Postal Code

34096

Country

Turkey

Facility Name

Novo Nordisk Investigational Site

City

Istanbul

ZIP/Postal Code

34098

Country

Turkey

Facility Name

Novo Nordisk Investigational Site

City

Istanbul

ZIP/Postal Code

34360

Country

Turkey

Facility Name

Novo Nordisk Investigational Site

City

Istanbul

ZIP/Postal Code

34371

Country

Turkey

Facility Name

Novo Nordisk Investigational Site

City

Istanbul

ZIP/Postal Code

34390

Country

Turkey

Facility Name

Novo Nordisk Investigational Site

City

Istanbul

ZIP/Postal Code

34722

Country

Turkey

Facility Name

Novo Nordisk Investigational Site

City

Istanbul

ZIP/Postal Code

34890

Country

Turkey

Facility Name

Novo Nordisk Investigational Site

City

Istanbul

Country

Turkey

Facility Name

Novo Nordisk Investigational Site

City

Izmir

ZIP/Postal Code

35100

Country

Turkey

Facility Name

Novo Nordisk Investigational Site

City

Izmir

ZIP/Postal Code

35340

Country

Turkey

Facility Name

Novo Nordisk Investigational Site

City

Kayseri

ZIP/Postal Code

38039

Country

Turkey

Facility Name

Novo Nordisk Investigational Site

City

Dubai

ZIP/Postal Code

4545

Country

United Arab Emirates

Facility Name

Novo Nordisk Investigational Site

City

Dubai

ZIP/Postal Code

7272

Country

United Arab Emirates

Facility Name

Novo Nordisk Investigational Site

City

Aberdeen

ZIP/Postal Code

AB25 1LD

Country

United Kingdom

Facility Name

Novo Nordisk Investigational Site

City

Birmingham

ZIP/Postal Code

B9 5SS

Country

United Kingdom

Facility Name

Novo Nordisk Investigational Site

City

Bristol

ZIP/Postal Code

BS10 5NB

Country

United Kingdom

Facility Name

Novo Nordisk Investigational Site

City

Coventry

ZIP/Postal Code

CV2 2DX

Country

United Kingdom

Facility Name

Novo Nordisk Investigational Site

City

Devon

ZIP/Postal Code

EX2 5DW

Country

United Kingdom

Facility Name

Novo Nordisk Investigational Site

City

Dundee

ZIP/Postal Code

DD1 9SY

Country

United Kingdom

Facility Name

Novo Nordisk Investigational Site

City

Edinburgh

ZIP/Postal Code

EH16 4SA

Country

United Kingdom

Facility Name

Novo Nordisk Investigational Site

City

Glasgow

ZIP/Postal Code

G31 2ER

Country

United Kingdom

Facility Name

Novo Nordisk Investigational Site

City

Guildford

ZIP/Postal Code

GU2 7XX

Country

United Kingdom

Facility Name

Novo Nordisk Investigational Site

City

Hull

ZIP/Postal Code

HU3 2RW

Country

United Kingdom

Facility Name

Novo Nordisk Investigational Site

City

Livington

ZIP/Postal Code

EH54 6PP

Country

United Kingdom

Facility Name

Novo Nordisk Investigational Site

City

London

ZIP/Postal Code

W2 1NY

Country

United Kingdom

Facility Name

Novo Nordisk Investigational Site

City

Manchester

ZIP/Postal Code

M6 8HD

Country

United Kingdom

Facility Name

Novo Nordisk Investigational Site

City

Norwich

ZIP/Postal Code

NR4 7TJ

Country

United Kingdom

Facility Name

Novo Nordisk Investigational Site

City

Nuneaton

ZIP/Postal Code

CV10 7DJ

Country

United Kingdom

Facility Name

Novo Nordisk Investigational Site

City

Plymouth

ZIP/Postal Code

PL6 8BQ

Country

United Kingdom

Facility Name

Novo Nordisk Investigational Site

City

St Helens

ZIP/Postal Code

WA9 3DA

Country

United Kingdom

Facility Name

Novo Nordisk Investigational Site

City

Swansea

ZIP/Postal Code

SA6 6NL

Country

United Kingdom

Facility Name

Novo Nordisk Investigational Site

City

Torquay

ZIP/Postal Code

TQ2 7AA

Country

United Kingdom

Facility Name

Novo Nordisk Investigational Site

City

West Midlands

ZIP/Postal Code

B71 4HJ

Country

United Kingdom

12. IPD Sharing Statement

Citations:

PubMed Identifier

30851070

Citation

Verma S, Bain SC, Monk Fries T, Mazer CD, Nauck MA, Pratley RE, Rasmussen S, Saevereid HA, Zinman B, Buse JB. Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials. Diabetes Obes Metab. 2019 Jul;21(7):1745-1751. doi: 10.1111/dom.13698. Epub 2019 Apr 2.

Results Reference

background

PubMed Identifier

30900349

Citation

Hinton W, Feher M, Munro N, Walker M, de Lusignan S. Real-world prevalence of the inclusion criteria for the LEADER trial: Data from a national general practice network. Diabetes Obes Metab. 2019 Jul;21(7):1661-1667. doi: 10.1111/dom.13710. Epub 2019 Apr 11.

Results Reference

background

PubMed Identifier

27295427

Citation

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.

Results Reference

result

PubMed Identifier

26855018

Citation

Petrie JR, Marso SP, Bain SC, Franek E, Jacob S, Masmiquel L, Leiter LA, Haluzik M, Satman I, Omar M, Shestakova M, Van Gaal L, Mann JF, Baeres FM, Zinman B, Poulter NR; LEADER investigators. LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial. J Hypertens. 2016 Jun;34(6):1140-50. doi: 10.1097/HJH.0000000000000890.

Results Reference

result

PubMed Identifier

26864124

Citation

Masmiquel L, Leiter LA, Vidal J, Bain S, Petrie J, Franek E, Raz I, Comlekci A, Jacob S, van Gaal L, Baeres FM, Marso SP, Eriksson M; LEADER investigators. LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial. Cardiovasc Diabetol. 2016 Feb 10;15:29. doi: 10.1186/s12933-016-0341-5.

Results Reference

result

PubMed Identifier

27320184

Citation

Satman I, R Rea R, Eriksson M, Mosenzon O, Pratley R, M Baeres F, D Orsted D, F Mann J; LEADER Trial Investigators. LEADER-6: Baseline renal function and associated factors in a high cardiovascular risk type 2 diabetes population. J Diabetes Complications. 2016 Nov-Dec;30(8):1631-1639. doi: 10.1016/j.jdiacomp.2016.06.001. Epub 2016 Jun 3.

Results Reference

result

PubMed Identifier

27274772

Citation

Rutten GE, Tack CJ, Pieber TR, Comlekci A, Orsted DD, Baeres FM, Marso SP, Buse JB; LEADER Investigators. LEADER 7: cardiovascular risk profiles of US and European participants in the LEADER diabetes trial differ. Diabetol Metab Syndr. 2016 Jun 2;8:37. doi: 10.1186/s13098-016-0153-5. eCollection 2016.

Results Reference

result

PubMed Identifier

24176437

Citation

Marso SP, Poulter NR, Nissen SE, Nauck MA, Zinman B, Daniels GH, Pocock S, Steinberg WM, Bergenstal RM, Mann JF, Ravn LS, Frandsen KB, Moses AC, Buse JB. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J. 2013 Nov;166(5):823-30.e5. doi: 10.1016/j.ahj.2013.07.012. Epub 2013 Oct 2.

Results Reference

result

PubMed Identifier

25275271

Citation

Steinberg WM, Nauck MA, Zinman B, Daniels GH, Bergenstal RM, Mann JF, Steen Ravn L, Moses AC, Stockner M, Baeres FM, Marso SP, Buse JB; LEADER Trial investigators. LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial. Pancreas. 2014 Nov;43(8):1223-31. doi: 10.1097/MPA.0000000000000229.

Results Reference

result

PubMed Identifier

25656058

Citation

Daniels GH, Hegedus L, Marso SP, Nauck MA, Zinman B, Bergenstal RM, Mann JF, Derving Karsbol J, Moses AC, Buse JB, Tuttle RM; LEADER Trial Investigators. LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations. Diabetes Obes Metab. 2015 May;17(5):477-86. doi: 10.1111/dom.12444. Epub 2015 Feb 23.

Results Reference

result

PubMed Identifier

28476871

Citation

Steinberg WM, Buse JB, Ghorbani MLM, Orsted DD, Nauck MA; LEADER Steering Committee; LEADER Trial Investigators. Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial. Diabetes Care. 2017 Jul;40(7):966-972. doi: 10.2337/dc16-2747. Epub 2017 May 5.

Results Reference

result

PubMed Identifier

28854085

Citation

Mann JFE, Orsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornoe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators. Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med. 2017 Aug 31;377(9):839-848. doi: 10.1056/NEJMoa1616011.

Results Reference

result

PubMed Identifier

29279300

Citation

Hegedus L, Sherman SI, Tuttle RM, von Scholten BJ, Rasmussen S, Karsbol JD, Daniels GH; LEADER Publication Committee on behalf of the LEADER Trial Investigators. No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial. Diabetes Care. 2018 Mar;41(3):620-622. doi: 10.2337/dc17-1956. Epub 2017 Dec 26.

Results Reference

result

PubMed Identifier

29627109

Citation

Marso SP, Nauck MA, Monk Fries T, Rasmussen S, Treppendahl MB, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial). Am J Cardiol. 2018 Jun 15;121(12):1467-1470. doi: 10.1016/j.amjcard.2018.02.030. Epub 2018 Mar 15.

Results Reference

result

PubMed Identifier

29760228

Citation

Verma S, Bhatt DL, Bain SC, Buse JB, Mann JFE, Marso SP, Nauck MA, Poulter NR, Pratley RE, Zinman B, Michelsen MM, Monk Fries T, Rasmussen S, Leiter LA; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial. Circulation. 2018 May 15;137(20):2179-2183. doi: 10.1161/CIRCULATIONAHA.118.033898. No abstract available.

Results Reference

result

PubMed Identifier

29898902

Citation

Nauck MA, Jensen TJ, Rosenkilde C, Calanna S, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial. Diabetes Care. 2018 Aug;41(8):1663-1671. doi: 10.2337/dc17-1825. Epub 2018 Jun 13.

Results Reference

result

PubMed Identifier

29903847

Citation

Zinman B, Marso SP, Christiansen E, Calanna S, Rasmussen S, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience. Diabetes Care. 2018 Aug;41(8):1783-1791. doi: 10.2337/dc17-2677. Epub 2018 Jun 14.

Results Reference

result

PubMed Identifier

29947247

Citation

Nauck MA, Tornoe K, Rasmussen S, Treppendahl MB, Marso SP; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial. Diab Vasc Dis Res. 2018 Sep;15(5):465-468. doi: 10.1177/1479164118783935. Epub 2018 Jun 27.

Results Reference

result

PubMed Identifier

30072400

Citation

Dhatariya K, Bain SC, Buse JB, Simpson R, Tarnow L, Kaltoft MS, Stellfeld M, Tornoe K, Pratley RE; LEADER Publication Committee on behalf of the LEADER Trial Investigators. The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial. Diabetes Care. 2018 Oct;41(10):2229-2235. doi: 10.2337/dc18-1094. Epub 2018 Aug 2.

Results Reference

result

PubMed Identifier

30354517

Citation

Verma S, Leiter LA, Mazer CD, Bain SC, Buse J, Marso S, Nauck M, Zinman B, Bosch-Traberg H, Rasmussen S, Michelsen MM, Bhatt DL. Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use. Circulation. 2018 Oct 9;138(15):1605-1607. doi: 10.1161/CIRCULATIONAHA.118.036862. No abstract available.

Results Reference

result

PubMed Identifier

30566006

Citation

Mann JFE, Fonseca V, Mosenzon O, Raz I, Goldman B, Idorn T, von Scholten BJ, Poulter NR. Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease. Circulation. 2018 Dec 18;138(25):2908-2918. doi: 10.1161/CIRCULATIONAHA.118.036418.

Results Reference

result

PubMed Identifier

30566004

Citation

Verma S, Poulter NR, Bhatt DL, Bain SC, Buse JB, Leiter LA, Nauck MA, Pratley RE, Zinman B, Orsted DD, Monk Fries T, Rasmussen S, Marso SP. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke. Circulation. 2018 Dec 18;138(25):2884-2894. doi: 10.1161/CIRCULATIONAHA.118.034516.

Results Reference

result

PubMed Identifier

30260088

Citation

Nauck MA, Buse JB, Mann JFE, Pocock S, Bosch-Traberg H, Frimer-Larsen H, Ye Q, Gray A; LEADER Publication Committee for the LEADER Trial Investigators. Health-related quality of life in people with type 2 diabetes participating in the LEADER trial. Diabetes Obes Metab. 2019 Mar;21(3):525-532. doi: 10.1111/dom.13547. Epub 2018 Oct 25.

Results Reference

result

PubMed Identifier

30392095

Citation

Zinman B, Nauck MA, Bosch-Traberg H, Frimer-Larsen H, Orsted DD, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Liraglutide and Glycaemic Outcomes in the LEADER Trial. Diabetes Ther. 2018 Dec;9(6):2383-2392. doi: 10.1007/s13300-018-0524-z. Epub 2018 Nov 3.

Results Reference

result

PubMed Identifier

30508430

Citation

Gilbert MP, Bain SC, Franek E, Jodar-Gimeno E, Nauck MA, Pratley R, Rea RR, Kerr Saraiva JF, Rasmussen S, Tornoe K, von Scholten BJ, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial. Ann Intern Med. 2019 Mar 19;170(6):423-426. doi: 10.7326/M18-1569. Epub 2018 Dec 4. No abstract available.

Results Reference

result

PubMed Identifier

35332654

Citation

Verma S, Al-Omran M, Leiter LA, Mazer CD, Rasmussen S, Saevereid HA, Sejersten Ripa M, Bonaca MP. Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease. Diabetes Obes Metab. 2022 Jul;24(7):1288-1299. doi: 10.1111/dom.14700. Epub 2022 Apr 11.

Results Reference

derived

PubMed Identifier

34704120

Citation

Heller SR, Geybels MS, Iqbal A, Liu L, Wagner L, Chow E. A higher non-severe hypoglycaemia rate is associated with an increased risk of subsequent severe hypoglycaemia and major adverse cardiovascular events in individuals with type 2 diabetes in the LEADER study. Diabetologia. 2022 Jan;65(1):55-64. doi: 10.1007/s00125-021-05556-7. Epub 2021 Oct 26.

Results Reference

derived

PubMed Identifier

33504496

Citation

Persson F, Bain SC, Mosenzon O, Heerspink HJL, Mann JFE, Pratley R, Raz I, Idorn T, Rasmussen S, von Scholten BJ, Rossing P; LEADER Trial Investigators. Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial. Diabetes Care. 2021 Apr;44(4):1020-1026. doi: 10.2337/dc20-1622. Epub 2021 Jan 27.

Results Reference

derived

PubMed Identifier

32744418

Citation

Verma S, McGuire DK, Bain SC, Bhatt DL, Leiter LA, Mazer CD, Monk Fries T, Pratley RE, Rasmussen S, Vrazic H, Zinman B, Buse JB. Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials. Diabetes Obes Metab. 2020 Dec;22(12):2487-2492. doi: 10.1111/dom.14160. Epub 2020 Sep 4.

Results Reference

derived

PubMed Identifier

32647053

Citation

Crowley MJ, McGuire DK, Alexopoulos AS, Jensen TJ, Rasmussen S, Saevereid HA, Verma S, Buse JB. Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial. Diabetes Care. 2020 Sep;43(9):e108-e110. doi: 10.2337/dc20-0437. Epub 2020 Jul 9. No abstract available.

Results Reference

derived

PubMed Identifier

32643857

Citation

Verma S, Bain SC, Honore JB, F E Mann J, A Nauck M, E Pratley R, Rasmussen S, Sejersten Ripa M, Zinman B, Buse JB. Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials. Diabetes Obes Metab. 2020 Nov;22(11):2193-2198. doi: 10.1111/dom.14140. Epub 2020 Aug 12.

Results Reference

derived

PubMed Identifier

32372454

Citation

Leiter LA, Bain SC, Bhatt DL, Buse JB, Mazer CD, Pratley RE, Rasmussen S, Ripa MS, Vrazic H, Verma S. The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials. Diabetes Obes Metab. 2020 Sep;22(9):1690-1695. doi: 10.1111/dom.14079. Epub 2020 Jun 3.

Results Reference

derived

PubMed Identifier

32366578

Citation

Buse JB, Bain SC, Mann JFE, Nauck MA, Nissen SE, Pocock S, Poulter NR, Pratley RE, Linder M, Monk Fries T, Orsted DD, Zinman B; LEADER Trial Investigators. Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial. Diabetes Care. 2020 Jul;43(7):1546-1552. doi: 10.2337/dc19-2251. Epub 2020 May 4.

Results Reference

derived

PubMed Identifier

32164886

Citation

Marso SP, Baeres FMM, Bain SC, Goldman B, Husain M, Nauck MA, Poulter NR, Pratley RE, Thomsen AB, Buse JB; LEADER Trial Investigators. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure. J Am Coll Cardiol. 2020 Mar 17;75(10):1128-1141. doi: 10.1016/j.jacc.2019.12.063.

Results Reference

derived

PubMed Identifier

32132141

Citation

Mann JFE, Fonseca VA, Poulter NR, Raz I, Idorn T, Rasmussen S, von Scholten BJ, Mosenzon O; LEADER Trial Investigators. Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease. Clin J Am Soc Nephrol. 2020 Apr 7;15(4):465-473. doi: 10.2215/CJN.11881019. Epub 2020 Mar 4.

Results Reference

derived

PubMed Identifier

31959650

Citation

Nauck MA, Kreiner E, Rasmussen S, Saevereid HA, Buse JB; LEADER Trial Investigators. Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912-1920. Diabetes Care. 2020 Feb;43(2):e30-e31. doi: 10.2337/dci19-0067. No abstract available.

Results Reference

derived

PubMed Identifier

31721979

Citation

Verma S, Bain SC, Buse JB, Idorn T, Rasmussen S, Orsted DD, Nauck MA. Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2019 Dec 1;4(12):1214-1220. doi: 10.1001/jamacardio.2019.3080.

Results Reference

derived

PubMed Identifier

31399438

Citation

Nauck MA, Muus Ghorbani ML, Kreiner E, Saevereid HA, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care. 2019 Oct;42(10):1912-1920. doi: 10.2337/dc19-0415. Epub 2019 Aug 9.

Results Reference

derived

PubMed Identifier

31282028

Citation

Tack CJ, Jacob S, Desouza C, Bain SC, Buse JB, Nauck MA, Petrie JR, Poulter NR, Pratley RE, Stegmann HVBK, Bosch-Traberg H, Startseva E, Zinman B; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial. Diabetes Obes Metab. 2019 Nov;21(11):2450-2458. doi: 10.1111/dom.13826. Epub 2019 Jul 7.

Results Reference

derived

PubMed Identifier

29693361

Citation

Wittbrodt ET, Eudicone JM, Bell KF, Enhoffer DM, Latham K, Green JB. Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials enrollment criteria to the US type 2 diabetes population. Am J Manag Care. 2018 Apr;24(8 Suppl):S146-S155.

Results Reference

derived

Links:

URL

http://novonordisk-trials.com

Description

Clinical Trials at Novo Nordisk

Learn more about this trial

Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results

We'll reach out to this number within 24 hrs

Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER®)

Diabetes, Diabetes Mellitus, Type 2

About this trial

Eligibility Criteria

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

1. Study Identification

2. Study Status

3. Sponsor/Collaborators

4. Oversight

5. Study Description

6. Conditions and Keywords

7. Study Design

8. Arms, Groups, and Interventions

10. Eligibility

12. IPD Sharing Statement

Learn more about this trial